全球医疗科技企业、总部位于日本东京的泰尔茂株式会社（Terumo Corporation）已达成协议，将以 15 亿美元收购 OrganOx 公司。OrganOx 是一家牛津大学衍生公司，致力于革新肾脏和肝脏移植技术。该交易尚需获得监管部门批准，一旦完成，将成为牛津大学有史以来规模最大的衍生公司收购案，同时也是英国大学衍生公司史上最重要的风险投资退出案例之一。
An agreement has been reached for the acquisition of OrganOx, a pioneering University of Oxford spinout transforming kidney and liver transplantation, by Terumo Corporation, a global medical technology company headquartered in Tokyo, Japan, for US$1.5 billion. The transaction, which is subject to regulatory and other approvals, would be the largest acquisition of an Oxford University spinout to date, and one of the most significant venture capital exits in UK university spinout history.
OrganOx 成立于 2008 年，由工程学教授康斯坦丁・库西奥斯（Constantin Coussios，获大英帝国勋章、英国皇家工程院院士、英国医学科学院院士）与移植外科医生彼得・弗兰德教授（Peter Friend，英国医学科学院院士）联合创立，其根源可追溯至牛津大学生物医学工程研究所与纳菲尔德外科科学系。如今，该公司已成为先进器官保存技术领域的领军者。
OrganOx 专注于研发器官保存技术，其技术能使供体器官在体外保持功能的时间远超传统手段。该公司采用 “常温机械灌注（NMP）” 技术，通过设备将温热的含氧液体输送至器官内部循环，模拟人体内环境。这一技术使临床医生能够实时评估器官功能，从而更科学地制定移植决策。
(OrganOx metra 设备灌注期间，器官保持完全温热状态)
Founded in 2008 by engineering professor Constantin Coussios OBE FREng FMedSci and transplant surgeon professor Peter Friend FMedSci, OrganOx originated from Oxford’s Institute of Biomedical Engineering and the Nuffield Department of Surgical Sciences. The company has since become a leader in advanced organ preservation technology.
OrganOx specialises in organ preservation devices that keep donor organs functioning outside the body for significantly longer than traditional methods. Using a technique known as Normothermic Machine Perfusion (NMP), its devices circulate warm, oxygenated fluid through the organ, replicating conditions inside the human body. This enables clinicians to assess organ function in real time and make better-informed decisions about transplantation.
(Organ during Metra Perfusion Fully Warm)
Swipe left for English
该技术显著增加了可用于移植的可用器官数量（包括来自边缘供体的器官），同时减少了紧急手术和夜间手术数量。截至目前，OrganOx 已在全球范围内支持超过 6000 例移植手术，并于近期荣获英国皇家工程院颁发的麦克罗伯特奖——该奖是英国历史最悠久、最负盛名的工程创新奖项。以表彰OrganOx在拯救生命、助力更多器官移植手术开展及缩短患者等待名单方面的突出贡献。
牛津大学是 OrganOx 的早期投资方，通过 “大学挑战种子基金” 为该公司提供概念验证资金，并通过 “衍生公司股权管理基金” 进一步追加投资，为公司初期发展提供了重要支撑。
(可通过空运及陆路运输是 OrganOx metra 设备的一大关键特性)
The technology has increased the number of viable organs available for transplant, including those from marginal donors, while reducing the need for emergency and night-time procedures. OrganOx systems have been used in more than 6,000 transplants worldwide and were recently recognised with The Royal Academy of Engineering's MacRobert Award, the longest running and most prestigious prize for UK engineering innovation, for its life-saving technology that is supporting more organ transplants and helping to cut waiting lists.
Oxford University was an early investor in OrganOx, supporting the company with proof-of-concept funding via the University Challenge Seed Fund and investing further through the Spinout Equity Management Fund.
(Transportability by air as well as by road is a key feature of the OrganOx metra device)
Swipe left for English
康斯坦丁・库西奥斯教授(牛津大学生物医学工程研究所所长、OrganOx 联合创始人)表示：“这项技术源于生物医学工程研究所内工程学与临床科学的深度合作，而牛津大学无可比拟的跨学科创新生态系统为这种合作提供了独特支持。从一开始，我们的目标就是解决移植领域的一大核心难题：延长器官保存时间，让更多原本无法移植的器官能够用于治疗。看到这一愿景在四大洲为患者带来福祉，令人无比欣慰。此次收购将进一步扩大牛津创新科学的全球影响力和影响范围。”
彼得・弗兰德教授(移植外科医生、两千-2022 年任牛津移植中心主任、OrganOx 联合创始人)表示：“作为一名临床医生，我亲眼目睹了传统器官保存方法的局限性。OrganOx 的技术正在彻底改变器官移植格局，对患者和外科医生都产生了深远影响。这一项目的成功，源于外科科学系与生物医学工程系两个学术部门的高效协作，而牛津大学在科研成果转化方面的全力支持。”
艾琳・特雷西教授(Irene Tracey，牛津大学校长)表示：“OrganOx的成功是牛津研究如何改变生活的例证。此次里程碑式的收购，不仅是对这项开创性技术的肯定，更彰显了我们创新生态系统的强大实力—— 跨学科深度协作、前瞻性战略投资与世界的科研基础。这对大学来说是一个值得骄傲的时刻，也标志着我们将通过的研究及相关衍生公司持续产生巨大影响力。”
（OrganOx metra 设备在移植前将肝脏维持在正常体温，并主动为其输送含氧血液、药物和营养物质)
亚当・沃克曼(Adam Workman，牛津大学科技创新公司投资与新创企业负责人)表示：“OrganOx的成功收购，是牛津大学创新生态系统的一个标志性事件，充分印证了我们科技创新公司模式的成熟性与对变革性科学进行早期投资的长远价值。”
Professor Constantin Coussios, Director of Oxford University's Institute of Biomedical Engineering and co-founder of OrganOx, said: 'This technology was born from a deep collaboration between engineering and clinical science within the Institute of Biomedical Engineering, uniquely enabled by Oxford’s unparalleled cross-disciplinary innovation ecosystem. From the outset our aim was to solve one of transplantation’s greatest challenges: preserving organs in a viable state for longer, so at to make it possible to assess and potentially transplant what was previously thought untransplantable. Seeing that vision realised for the benefit of patients across four continents has been incredibly rewarding, and this acquisition will further enhance the global reach and impact of Oxford’s innovative science.'
Professor Peter Friend, transplant surgeon, Director of the Oxford Transplant Centre from 两千 to 2022 and co-founder of OrganOx, said: 'As a clinician, I’ve seen first-hand the limitations of traditional organ preservation. OrganOx technology is transforming the landscape of organ transplantation, with huge impact on both patients and surgeons. The success of this venture results from a highly effective synergy between two academic departments, Surgical Sciences and Biomedical Engineering, and the University of Oxford’s support has been instrumental in translating our research into real-world impact.'
Professor Irene Tracey, Vice-Chancellor of the University of Oxford, said: 'OrganOx’s success is a powerful example of how Oxford’s research can transform lives. This landmark acquisition not only celebrates a pioneering technology but also affirms the strength of our innovation ecosystem - built on deep collaboration, bold investment, and world-class science. It marks a proud moment for the University and signals the scale of impact we will continue to deliver through our world-leading research and associated spinouts.'
(The OrganOx metra device maintains the liver at normal body temperature prior to transplantation and actively delivers oxygenated blood, medications and nutrients)
Adam Workman, Head of Investments and Ventures at Oxford University Innovation, commented: 'OrganOx’s acquisition is a landmark moment for Oxford University’s innovation ecosystem. It reflects the strength of our spinout model and the long-term value of investing in transformative science from the earliest st
